Search results with tag "Bortezomib"
VELCADE (bortezomib) for Subcutaneous Administration Site ...
www.velcade.comCONTRAINDICATIONS: VELCADE (bortezomib) is contraindicated in patients with hypersensitivity (not including local reactions) to bortezomib, boron, or mannitol, including anaphylactic reactions. VELCADE is contraindicated for intrathecal administration.
DARATUMUMAB WITH BORTEZOMIB AND …
nssg.oxford-haematology.org.ukBortezomib** 1.3 mg/m2 TWICE a week given as SC bolus Days 1,4,8 and 11 Dexamethasone 20mg PO once daily on the day of and day after bortezomib injection Days 2**, 4, 5, 8, 9, 11 and 12 *On day 1, dexamethasone is given as pre-med 1 …
DARATUMUMAB WITH BORTEZOMIB, THALIDOMIDE AND …
nssg.oxford-haematology.org.ukBortezomib 1.3 mg/m2 given SC bolus Days 1, 8, 15 and 22 Thalidomide 50 -100 mg PO (preferably nocte) Start at 50mg and increase as tolerated Daily Dexamethasone 40 mg PO (this includes dexamethasone pre-meds) i.e. on daratumumab days, 20mg is to be administered in addition to the 20mg pre-med
Subcutaneous Bortezomib (Velcade ), …
www.londoncanceralliance.nhs.ukSubcutaneous Bortezomib (Velcade®), Cyclophosphamide & Dexamethasone (VCD) for Multiple Myeloma Page 1 of 4 Reason for Update: SC route licensed , include twice weekly protocol Approved by Consultant: M Streetly 05/12/2012
Daratumumab, bortezomib & dexamethasone (DVd)
www.swagcanceralliance.nhs.ukBortezomib: withhold for grade 3 non-haematological or grade 4 haematological toxicities. Once toxicity has resolved, re-initiate at reduced dose (1.3 mg/m2 reduced to 1.0 mg/m2; 1.0 mg/m2 reduced to 0.7 mg/m2). If the toxicity is not resolved or if it recurs at the lowest dose, discontinue unless benefit outweighs risk. Renal impairment
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
www.ema.europa.euPatients who experience bortezomib-related neuropathic pain and/or peripheral neuropathy are to be managed as presented in Table1 (see section4.4). Patients with pre-existing severe neuropathy may be treated withVELCADE only after careful risk/benefit assessment. Table1: Recommended* posology modifications for bortezomib-related neuropathy
Prescribing Information | VELCADE® (bortezomib)
www.velcade.comVELCADE® (bortezomib) for injection, for subcutaneous or intravenous use Initial U.S. Approval: 2003 -----INDICATIONS AND USAGE----- VELCADE is a proteasome inhibitor indicated for: treatment of adult patients with multiple myeloma (1.1) treatment of adult patients with mantle cell lymphoma (1.2)
DRUG NAME: Bortezomib - BC Cancer
www.bccancer.bc.caBortezomib is a reversible inhibitor of the 26S proteasome, a protein complex that degrades ubiquitinated proteins. This inhibition affects cancer cells in a number of ways, including altering regulatory proteins, which control cell cycle progression and Nuclear Factor kappa B activation. Inhibition of the proteasome results in cell cycle ...
DOSE BANDING TABLES - HSE.ie
www.hse.iebortezomib subcutaneous injection (version 1) The dose bands used in this table are constructed based on a 2.5mg/ml concentration of bortezomib Dose rounding has been applied to the lower end of this table in order to facilitate the nearest measurable volume
PRODUCT MONOGRAPH BORTEZOMIB FOR INJECTION
www.drreddys.com5 Tumour L ysis Syndrome: Because bortezomib for injection is a cytoto xic agent and can rapi dly kill m alignant plas m a cells, the co m plications of tu m our lysis syndro m e may occur.
VELCADE BORTEZOMIB FÓRMULA CUALI Y …
www.janssen.comPag. 3 de 44 luego de la administración de dosis únicas o repetidas de 1,0 mg/m2 o 1,3 mg/ m2 a pacientes con mieloma múltiple. Esto sugiere que el bortezomib se distribuye ampliamente a los tejidos periféricos.
VELCADE®(bortezomib) REIMBURSEMENT ASSISTANCE …
www.velcade.comVELCADE®(bortezomib) REIMBURSEMENT ASSISTANCE PROGRAM Please complete the information below and fax to the VELCADE Reimbursement Assistance Program at (800) 891-9843 or mail to PO Box 52100, Phoenix,
Reference ID: 4110010 - VELCADE
www.velcade.com3/38 . FULL PRESCRIBING INFORMATION . 1 INDICATIONS AND USAGE . 1.1 Multiple Myeloma . VELCADE ® (bortezomib) is indicated for the treatment of patients with multiple myeloma.
NEW HCPCS CODE FOR DOXIL - Northern New …
www.nnecos.orgINDICATIONS • DOXIL® is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy • ® DOXIL® in combination with VELCADE (bortezomib) is indicated for the treatment of patients with multiple myeloma who have not previously received
BC Cancer Protocol Summary for the Treatment of Multiple ...
www.bccancer.bc.ca• The last bortezomib and cyclophosphamide dose should be given at least 14 days prior to stem cell collection. • Platelet count less than 30 x 10. 9 /L may require transfusion support • If absolute neutrophil count (ANC) less than 0.5 x 10: 9 /L may require giving filgrastim :
Velcade (bortezomib) - Caremark
www.caremark.comtreatment of previously treated or relapsed multiple myeloma as part of ANY of the following regimens in patients who will be receiving the same therapy as their primary chemotherapy, were transplant candidates, and the relapse occurred at least 6 months after their primary
Rejection after Lung Transplantation?
www.thoracic.orgrituximab and bortezomib (Velcade®), that reduce the number of B cells may be used. A repeat blood test, to check for antibodies is done a few weeks later to see how well these treatments worked. A person can have multiple episodes of acute rejection over time. Repeated episodes of acute rejection increase the risk of developing chronic rejection.
Sr. Drug Generic Name of the Medicine Unit Size MRP ...
janaushadhi.gov.in82 809 Bortezomib Injection 3.5 mg Vial Vial 3188. 00 Anticancer/Oncology 83 819 Capecitabine Tab I.P 500mg 10's 420.0 0 Anticancer/Oncology 84 851 Dacarbazine Injection 200mg VIAL Vial 188.0 0 Anticancer/Oncology 85 853 Daunorubicin HCl Injection 20mg vial Vial 204.0 0 Anticancer/Oncology 86 916 Imatinib mesylate Tablets IP 400mg 10's
ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS
www.ema.europa.euBortezomib should be administered via subcutaneous injection (1.3 mg/m2 body surface area) twice weekly on days 1, 4, 8 and 11 of each 21-day. For additional information on the dose, schedule and dose adjustments of medicinal products administered with
CYCLOPHOSPHAMIDE / BORTEZOMIB/ …
nssg.oxford-haematology.org.ukMyeloma group This is a controlled document and therefore must not be changed of MM.11 CyBorDex- Amyloidosis Authorised by …
BORTEZOMIB THALIDOMIDE AND DEXAMETHASONE …
nssg.oxford-haematology.org.ukbortezomib dose At least 72 hours should elapse between consecutive doses of bortezomib. Bortezomib can also be administered weekly on days 1, 8 and 15 in a 21 days cycle in selected patients. If neurotoxicity precludes completing planned therapy, consider completing the intended number of VTD cycles after the autologous transplant.
Similar queries
VELCADE (bortezomib) for Subcutaneous Administration Site, Bortezomib, Bortezomib Injection, Cyclophosphamide, SUMMARY OF PRODUCT CHARACTERISTICS, PRESCRIBING INFORMATION, Bortezomib) for, Injection, Bortezomib for injection, NEW HCPCS CODE FOR DOXIL, Velcade, Velcade bortezomib, Caremark, Treatment, Multiple myeloma, Regimens, Lung Transplantation, CYCLOPHOSPHAMIDE / BORTEZOMIB, CyBorDex- Amyloidosis